Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Matrix Laboratories, a subsidiary of Mylan, has received approval for its abbreviated new drug application (ANDA) from the Food and Drug Administration (FDA) for Pantoprazole Sodium delayed-release (DR) tablets USP, 20mg (base) and 40mg (base) to treat irritation of the esophagus caused by gastroesophageal reflux disease (GERD).
Subscribe to our email newsletter
Matrix claims that Pantoprazole Sodium DR tablets, a proton pump inhibitor drug, are generic version of Wyeth‘s Protonix DR tablets.
Protonix is in a group of drugs called proton pump inhibitors which decrease the amount of acid produced in the stomach.
Protonix is used to treat erosive esophagitis (damage to the esophagus from stomach acid) and other conditions involving excess stomach acid such as Zollinger-Ellison syndrome.